1. South Korea Stocks

  2. •

    Consumer non-durables

  3. •

    Household/Personal care
NeoPharm Co., Ltd.

NeoPharm Co., Ltd.

KKRX:092730
23,350.00
KRW
+200.00
(+0.86%)
1,873.90EPS
9.05P/E
265.12BMarket Cap
Nov 06Next Earn
NeoPharm Co., Ltd.
KRX:092730
(Korea Stock Exchange)

Recent

price

23,350.00

P/E

ratio

9.05

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
KRW
988.76
1,143.49
1,260.78
1,370.82
1,799.24
2,543.91
2,993.3
3,790.79
4,685.02
5,557.9
5,217.83
5,621.86
5,435.98
6,208.25
7,608.96
8,450.99
8,746.04
Revenue per Share
87
61.02
43.5
129
180.5
241
547
817
1,086.5
1,285
1,159
1,132.5
1,088.5
1,484.07
1,474.61
1,778.81
1,873.9
Basic EPS, GAAP
-82.39
207.34
21.69
119.91
451.92
375.44
547.65
675.34
996.03
1,163.51
1,044.74
1,355.62
1,109.41
155.66
994.39
1,725.49
1,490.69
Free Cash Flow per Basic Share
39.69
29.26
37.32
37.83
50.9
125.1
124.95
175.01
250.05
307.03
374.95
325.01
349.97
350
375
600
- -
Dividend per Share
1,988.96
2,015.91
2,019.4
2,094.28
2,201.26
2,305.72
2,726.05
3,362.92
4,190.2
6,757.3
7,526.09
8,330.85
9,092.03
10,231.02
11,308.86
12,489.82
12,282.04
Book Value per Share
1,563.94
1,617.69
1,675.18
1,808.31
2,005.2
2,228.15
2,639.16
3,277.92
4,107.46
6,604.88
7,373.9
8,199.46
8,977.82
10,088.01
11,184.13
12,377.11
12,169.07
Tangible Book Value per Share
15
15
15
15
14
14
14
14
14
15
16
16
16
16
16
16
16
Basic Weighted Avg Shares
14,661
16,944
18,774
20,138
25,603
35,965
42,369
53,634
66,275
83,240
81,625
87,931
85,033
97,105
119,014
132,184
136,799
Sales/Revenue/Turnover
2.07
7.08
1.11
10.66
19.54
17.4
22.77
26.17
28.91
27.58
26.83
25.51
25.21
26.06
20.71
21.77
21.71
Operating Margin (%)
1,522
965
903
975
929
928
832
795
835
1,209
1,494
1,500
1,616
1,673
3,150
3,156
3,241
Depreciation Expense
1,290
904
648
1,895
2,568
3,407
7,742
11,559
15,370
19,245
18,131
17,713
17,027
23,213
23,065
27,823
29,310
Net Income, GAAP
- -
- -
- -
2.72
30.96
21.16
17.97
17.62
22.31
18.25
20.95
25.69
27
20.97
23.65
13.76
14.72
Effective Tax Rate (%)
8.8
5.34
3.45
9.41
10.03
9.47
18.27
21.55
23.19
23.12
22.21
20.14
20.02
23.9
19.38
21.05
21.43
Profit Margin (%)
9,366
10,978
12,666
15,192
17,891
15,672
25,951
35,032
46,043
88,849
98,675
108,543
118,133
117,558
137,922
155,442
152,515
Working Capital
161
354
- -
900
- -
- -
- -
- -
400
4,000
19
102
- -
430
129
847
575
LT Debt
29,473
29,872
29,924
30,336
31,146
32,624
38,571
47,582
59,287
105,693
117,718
130,305
142,211
160,026
176,885
195,356
192,107
Total Equity
- -
- -
- -
6.75
10.91
15.12
21.42
25.8
26.28
21.19
14.52
12.85
11.11
12.83
10.87
12.96
13.4
Return on Invested Capital (%)
- -
- -
- -
6.18
8.2
10.61
21.72
26.8
28.63
22.65
15.64
14.03
12.46
15.3
13.64
14.87
15.91
Return on Capital (%)
4.46
3.05
2.17
6.29
8.36
10.69
21.75
26.83
28.76
23.33
16.23
14.28
12.5
15.36
13.69
14.95
15.98
Return on Common Equity (%)

Capital Structure

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
693
1,068
1,076
LT Borrowings
- -
- -
- -
LT Finance Leases
667
847
575
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
16
16
16
Market Capitalization
276,225
287,330
265,119

Working Capital

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
167,467
176,462
184,604
Cash, Cash Equivalents & STI
134,062
141,739
147,590
Accounts Receivable, Net
11,351
10,612
11,722
Inventories
14,414
15,577
16,720
Total Current Liabilities
17,899
21,020
32,090
Payables & Accruals
- -
- -
- -
ST Debt
693
1,068
1,076
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
20.92%
10.67%
10.44%
Free Cash Flow
67.22%
107.59%
73.52%
Net Income, GAAP
27.91%
10.03%
20.63%
Sales/Revenue/Turnover
14.39%
10.45%
11.07%
Total Cash Common Dividend
- -
- -
60%

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
28,215
30,621
26,151
34,027
119,014
2025
31,609
31,982
32,196
36,397
132,184
2026
36,224
- -
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
195.5
188
138.5
430.56
1,474.61
2025
456.28
451.81
438.54
432.19
1,778.81
2026
551.37
- -
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
375
2025
- -
- -
- -
- -
600
2026
- -
- -
- -
- -
- -
Similar Companies
Procter & Gamble Company (The) (NYSE:PG)
Cupid Limited (NSE:CUPID)
Hindustan Unilever Limited (NSE:HINDUNILVR)
Colgate-Palmolive (India) Limited (NSE:COLPAL)
Dabur India Limited (NSE:DABUR)
e.l.f. Beauty, Inc. (NYSE:ELF)
Business
NeoPharm Co. Ltd. (092730.KS) develops, manufactures and sells dermatological skincare products primarily targeting sensitive, dry and atopic skin conditions; core offerings include the Atopalm brand featuring non-steroid pseudo-ceramide (PC-9S) and multi-lamellar emulsion (MLE) technology in cleansing creams, lotions and moisturizers; Real Barrier dermo-cosmetics for skin barrier repair; ZEROID solutions for sensitive, dry, oily or troubled skin; Derma-B body moisturizers; MISSION ATHLETICARE sport care products; and DermArtlogy personalized consulting cosmetics, with additional facial foams, body washes and therapy lotions under MIMIC System of Stratum Corneum. Founded in 2000 and headquartered in Daejeon, South Korea, the company operates mainly in the household and personal products sector, serving domestic and international markets including the United States, Russia, China, Germany, Indonesia, Malaysia, Pakistan and Singapore through exports. Recent developments encompass strong revenue growth to 119 billion KRW in 2024 from 97 billion KRW in 2023 driven by brand expansions such as Real Barrier's designation as an official cosmetic brand and ZEROID's wins at the 2025 Olive Young Awards, alongside sustained R&D focus on skin homeostasis technologies amid quarterly operating profits averaging 5-7 billion KRW in 2024.